Beyond Domestic Competition: China's Medical Device Industry Targets a $500 Billion Global Market – The Ultimate Test of Internationalization Capabilities

Over the past two decades, the growth narrative of domestically produced medical devices in China has primarily revolved around “import substitution.” From low-value consumables to high-end imaging equipment, Chinese manufacturers have repeatedly broken through technical barriers in the domestic market, gradually converting the market share of imported products into growth space for homegrown brands. However, this story now requires a new chapter.

With the normalization of centralized procurement, intensifying competition within the sector, and narrowing profit margins, the “comfort zone” in the Chinese market is disappearing. Meanwhile, according to data from Fortune Business Insights, the global medical device market reached approximately $572.3 billion in 2025, several times larger than that of China. Amid this contraction at home and expansion abroad, “going global” has shifted from an optional strategy to an imperative for enterprises.

Zhu Qizhang, Medical Device Industry Analyst at China Securities (CSC)Having long tracked the medical device sector, he views global expansion not as a spur-of-the-moment trip, but as a marathon requiring strategic resolve, systemic capabilities, and risk awareness. Companies that truly establish a firm foothold overseas must build systemic advantages across dimensions such as product, patents, distribution channels, and after-sales service.

Overseas market opportunities are evident.

Taking medical imaging equipment as an example, according to statistics from Fortune Business Insights, the global market size in 2025 is approximately $44.3 billion. Developed markets such as Europe, the United States, and Japan hold the majority share, while developing countries exhibit strong demand for cost-effective products. This aligns well with the cost advantages of Chinese manufacturers.

However, what has further solidified companies’ resolve is domestic pressure. Volume-based procurement (VBP) has expanded from high-value consumables to in vitro diagnostics (IVD), and even to medical equipment, squeezing companies on both volume and price fronts. Competition within these sectors has become increasingly fierce, putting pressure on revenues and profits. Zhu Qizhang pointed out, “Many companies are experiencing a significant slowdown in growth domestically; the market has turned into a red ocean, making international expansion an inevitable choice.”

From an internal perspective, domestic enterprises have also acquired the capability to “go global.”

Over the past decade, cumulative investment in R&D has driven a qualitative transformation—shifting from follower-style innovation to incremental and even pioneering invention, with the performance of certain products now matching or even surpassing that of international giants. United Imaging Healthcare’s whole-body PET/CT systems and 5T MRI scanners, as well as Mindray’s patient monitors, have all established strong reputations in overseas markets. Meanwhile, companies’ overseas distribution channels and production capacity layouts are becoming increasingly sophisticated, transforming the “Made in China” label from one associated with low cost to one synonymous with reliability.

"Amidst pressure from both domestic and international fronts, going global has become an inevitable choice."

“Going global with medical devices is far more complex than with home appliances or consumer electronics,” Zhu Qizhang emphasized. Taking medical equipment as an example, the sale of a device is merely the beginning; subsequent installation, training, maintenance, and consumables supply are all indispensable.

He summarized the four core capabilities that enterprises must possess:

R&D and Patents: The “Passport” for Global Expansion.In Western markets, progress is virtually impossible without independent intellectual property rights. MGI Tech engaged in years of patent litigation with Illumina; although it ultimately prevailed, the process consumed substantial resources. Micro-Tech’s dispute with Boston Scientific was settled through an agreement to pay annual licensing fees of $2.4 million. These cases serve as a reminder to latecomers: patent portfolio development must outpace market expansion.

Sales models must be adapted to local conditions.The U.S. market favors direct sales, as hospitals and group purchasing organizations require in-depth academic support; in contrast, distribution dominates in Europe and developing countries, where distributors’ local resources are critical. Mindray’s approach offers valuable lessons: starting with foreign trade, establishing overseas offices, and then transitioning to direct sales in key markets, thereby expanding its customer base from grassroots hospitals to top-tier medical centers.

Production Layout Is Key to Risk Hedging.Fluctuations in U.S.-China tariffs have caught many companies off guard. Following the 2025 tariff adjustments, manufacturers of low-value medical consumables were hit hardest, with products such as surgical gloves subjected to an additional 25% tariff. In response, companies like Intco Medical and Haitai Optoelectronics have established overseas production facilities, both to circumvent tariffs and to meet overseas customers’ demands for supply chain diversification.

After-sales maintenance is the cornerstone of building trust.Medical equipment has a long service life, and once issues arise, response speed directly impacts clinical trust. United Imaging has established an overseas service team of over 1,000 professionals to address this “last mile” challenge. Zhu Qizhang specifically noted that many end customers choose Chinese enterprises precisely for their timely service response capabilities.

Of course, these capacity-building efforts require significant upfront investment from enterprises, which may face pressure from losses. However, as the scale of overseas operations expands, companies will enter a phase of profit realization—a process that reflects the principle of achieving breakthrough success through sustained accumulation.

From the perspective of corporate practice, product globalization can be broadly categorized into three types.

Market-OrientedRepresented by Mindray Medical. Starting from distribution and foreign trade, it gradually established overseas offices and regional centers, then transitioned to direct sales in certain markets by building localized sales teams. Its customer base has expanded from grassroots levels to the high-end segment, while its competitive advantage has evolved from cost-effectiveness to superior performance.

Technology-DrivenRepresented by United Imaging Healthcare. Leveraging original patents and product innovation, it directly targets the high-end markets in Europe and the United States, conducting clinical trials and regulatory certifications. After obtaining product certification, it can either sell independently or promote through license-out arrangements.

Customer-OrientedCommonly seen among upstream medical device manufacturers and low-value consumables companies. These firms have established stable partnerships with major overseas clients, resulting in a high proportion of overseas revenue.

In addition to product exports,External M&AIt represents another accelerated growth path. Mergers and acquisitions (M&A) have been indispensable to the growth trajectories of leading global medical device companies over the past two to three decades, with many firms achieving scale through continuous acquisitions. Chinese enterprises are following suit, leveraging acquisitions to complete their product portfolios, secure channel resources, and accelerate their overseas expansion.

These pathways present markedly different landscapes across various subsectors.

Medical Device Sector, while sectors such as medical imaging and endoscopy boast large market sizes, and emerging fields like surgical robots are experiencing rapid growth, the overseas market share of Chinese-made products remains extremely low, with the exception of patient monitors and ventilators.Upstream of the Medical Device IndustryLeveraging core underlying technologies and maintaining deep partnerships with global industry leaders, these companies demonstrate robust financial performance. To succeed in overseas markets, they must ensure product quality, cost competitiveness, and stable mass production capabilities. Additionally, some international clients require suppliers to establish manufacturing facilities abroad to achieve supply chain diversification.

IVD SectorThe market is vast, with significant opportunities in chemiluminescence and molecular diagnostics. Snibe has demonstrated outstanding performance, but the localization of reagents remains a challenge.High-Value ConsumablesGlobal expansion poses the greatest challenges, with stringent requirements for clinical data; most companies remain in the early stages.Low-Value ConsumablesThis is a traditional area of strength for Chinese enterprises. Domestic manufacturers hold significant advantages in production capacity and cost for categories such as gloves and dressings. Some companies have established overseas factories to mitigate the impact of tariffs.

In summary, the choice of international expansion strategy is closely tied to a company’s industry sector, product characteristics, and resource endowments. There is no one-size-fits-all model; only the approach best suited to each company’s unique circumstances. Those enterprises that can precisely align their expansion pathways with the specific dynamics of their sectors are gradually widening the gap between themselves and their competitors in the global market.

Capability is the foundation, but risk is the true test. Zhu Qizhang has outlined several categories of risks that Chinese-made medical device companies may encounter when expanding into overseas markets.

Patent LitigationIt is the first hurdle. In European and American markets, patent disputes are often the first obstacle encountered by Chinese manufacturers. Companies need to conduct FTO (Freedom to Operate) analysis in advance, and patent layout must stay ahead of the market.

Product RecallIt was an even more severe blow. For example, the massive recall of Philips’ home ventilators in 2021 inflicted substantial losses on the company and eroded market confidence in similar products. Given the U.S. FDA’s stringent regulatory oversight, any product quality issues can have a long-lasting impact on brand trust.

TariffIt has been one of the most significant variables in recent years. The 2025 adjustments to U.S.-China tariff policies have had a substantial impact on the secondary market and the internationalization strategies of certain companies. While most companies derive a relatively small proportion of their revenue from overseas, with an even smaller share coming from the United States, those with higher U.S. revenue exposure—such as manufacturers of low-value consumables and upstream medical device suppliers—have already established or are planning to establish overseas production bases to mitigate the impact of tariffs.

Other risks also includeSupply chain disruptions, rising logistics costs, channel inventory overhang, distributor attritionetc., all require advance planning by enterprises.

In the face of these risks, how can one assess whether a company has the capability to navigate through hidden reefs?

Zhu Sigang proposed several key dimensions for consideration. The first is the necessity of global expansion—companies facing slowing domestic growth and intense competition in their sectors have stronger incentives to go overseas and are more likely to maintain strategic focus under pressure. The second is the capability for global expansion, which should be evaluated across several specific levels:Are the product and patent layouts forward-looking? Is the local sales team solidly built? What is the progress of overseas production bases? Are core components independently controllable?。

Regarding valuation logic, many companies are experiencing high overseas growth rates and a continuously increasing proportion of overseas revenue, suggesting that domestic and international markets could be valued separately. An analysis of leading global medical device companies reveals that firms in innovative sectors with high growth potential command higher valuations, while those with steady but slower growth receive lower valuations. Most Chinese companies are in the early stages of international expansion and may warrant higher valuations, provided their capabilities can withstand verification.

Currently, the global top 20 medical device companies remain dominated by enterprises from Europe, the United States, and Japan, but Chinese companies are closing in, with Mindray Medical already ranking among the top 30 worldwide. Zhu Qizhang believes that more Chinese enterprises will join this ranks in the future.

It is worth noting that Chinese domestic enterprises are no longer mere followers. In multiple niche segments, the product performance and innovative capabilities of Chinese companies have become globally competitive. Zhu Qizhang stated that future investment opportunities in medical devices lie in focusing on companies that truly possess internationalization capabilities.

Going global is a marathon, not a 100-meter sprint. It tests strategic resolve, systemic capabilities, and risk management prowess. Enterprises that can translate the advantages of Chinese manufacturing into global brand strength will ultimately secure their place on the world map of medical devices.

And this is precisely the ultimate answer to this global examination of capabilities.